Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN5501 in Refractory Primary Immune Thrombocytopenia
NCT06337474Phase 1Recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Aug 2024
- Primary completion
- Jul 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KN5501 in immune thrombocytopenia (ITP), sponsored by Changzhou Second People's Hospital. Primary endpoints: Incidence of Dose Limiting Toxicity at 52 weeks and Treatment Emergent Adverse Events at 52 weeks. Started Aug 2024; status: recruiting.
02
Drugs
KN5501
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06337474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06337474.